鈣調磷酸酶抑制劑在特發性炎性肌病相關性間質性肺病中的研究進展_Chinese Journal of Respiratory and Critical Care Medicine

Authors：

任禎鈺 ,  唐小葵

重慶醫科大學附屬第一醫院呼吸與危重癥醫學科（重慶 400016）;

Corresponding?author：

唐小葵, Email: txk1200@126.com

Keywords：

DOI：

10.7507/1671-6205.202304001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 任禎鈺, 唐小葵. 鈣調磷酸酶抑制劑在特發性炎性肌病相關性間質性肺病中的研究進展. Chinese Journal of Respiratory and Critical Care Medicine, 2023, 22(9): 679-684. doi: 10.7507/1671-6205.202304001 Copy

1.	Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol, 2020, 16(3): 167-178.
2.	Gizinski AM, Fox DA. T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol, 2014, 26(2): 204-210.
3.	Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc, 2004, 36(2 Suppl): 25S-32S.
4.	F?rre O. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. Arthritis Rheum, 1994, 37(10): 1506-1512.
5.	Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis, 1988, 47(2): 127-133.
6.	Caccavo D, Laganà B, Mitterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum, 1997, 40(1): 27-35.
7.	Filaci G, Cutolo M, Basso M, et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford), 2001, 40: 1431-1432.
8.	Cantini F, Salvarani C, Niccoli L, et al. Treatment of thrombophlebitis of Beh?et's disease with low dose cyclosporin A. Clin Exp Rheumatol, 1999, 17(3): 391-392.
9.	Watanabe N, Sakamoto K, Taniguchi H, et al. Efficacy of combined therapy with cyclosporin and low-dose prednisolone in interstitial pneumonia associated with connective tissue disease. Respiration, 2014, 87(6): 469-477.
10.	Wu W, Guo L, Fu Y, et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol, 2021, 60(2): 293-304.
11.	馮娜, 彭守春, 李學任. 抗黑色素瘤分化相關基因5抗體陽性快速進展型間質性肺疾病的治療進展. 醫療裝備, 2021, 34: 187-189.
12.	Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol, 2008, 35(2): 254-259.
13.	Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol, 2005, 32(9): 1719-1726.
14.	Fujisawa T. Management of myositis-associated interstitial lung disease. Medicina (Kaunas), 2021, 57(4): 347.
15.	Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum, 2020, 50(4): 776-790.
16.	Abe Y, Kusaoi M, Tada K, et al. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford), 2020, 59(4): 767-771.
17.	Nakazawa M, Kaneko Y, Takeuchi T. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study. Clin Rheumatol, 2018, 37(3): 765-771.
18.	Cavagna L, Caporali R, Abdì-Alì L, et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol, 2013, 40(4): 484-492.
19.	Go DJ, Park JK, Kang EH, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int, 2016, 36(1): 125-131.
20.	Lian L, Li M, Li Y, et al. Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: A retrospective analysis. Medicine (Baltimore), 2022, 101(24): e29108.
21.	Fujisawa T, Hozumi H, Kamiya Y, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: a randomized, open-label trial. Respirology, 2021, 26(4): 370-377.
22.	中國研究型醫院學會呼吸病學專業委員會. 特發性炎性肌病相關間質性肺疾病診斷和治療中國專家共識. 中華結核和呼吸雜志, 2022, 45(7): 635-650.
23.	Kaneko Y, Kawahito Y, Kojima M, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis - a systematic review and meta-analysis. Mod Rheumatol, 2021, 31(1): 61-69.
24.	Lee YH, Woo JH, Choi SJ, et al. Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Scand J Rheumatol, 2010, 39(4): 271-278.
25.	Matsubara S, Kondo K, Sugaya K, et al. Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Clin Rheumatol, 2012, 31(10): 1493-1498.
26.	Shimojima Y, Ishii W, Matsuda M, et al. Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/ dermatomyositis: a retrospective study. BMC Musculoskelet Disord, 2012, 13: 228.
27.	Yokoyama Y, Furuta S, Ikeda K, et al. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Mod Rheumatol, 2015, 25(6): 888-892.
28.	Suzuki K, Kameda H, Amano K, et al. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatol Int, 2011, 31(6): 757-763.
29.	Konma J, Kotani T, Shoda T, et al. Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: A retrospective study. Mod Rheumatol, 2018, 28(6): 1009-1015.
30.	Yamano Y, Taniguchi H, Kondoh Y, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology, 2018, 23: 1041-1048.
31.	Witt LJ, Demchuk C, Curran JJ, et al. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther, 2016, 36: 46-52.
32.	Suzuka T, Kotani T, Takeuchi T, et al. Efficacy and safety of oral high-trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositis. Int J Rheum Dis, 2019, 22(2): 303-313.
33.	Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol, 2020, 72(3): 488-498.
34.	Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet, 1999, 353(9166): 1762-1763.
35.	Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum, 2005, 52(8): 2439-2446.
36.	Labirua-Iturburu A, Selva-O'Callaghan A, Martínez-Gómez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol, 2013, 31(3): 436-439.
37.	Sharma N, Putman MS, Vij R, et al. Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort. J Rheumatol, 2017, 44(11): 1612-1618.
38.	Hozumi H, Fujisawa T, Nakashima R, et al. Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis. J Rheumatol, 2019, 46(5): 509-517.
39.	Chen Y, Bai Z, Zhang Z, et al. The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: a retrospective and prospective study. Front Immunol, 2022, 13: 978429.
40.	Takei R, Yamano Y, Kataoka K, et al. Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease. Respir Investig, 2020, 58(2): 83-90.
41.	Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity, 2006, 39(3): 233-241.
42.	Isoda K, Kotani T, Takeuchi T, et al. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. Rheumatol Int, 2017, 37(8): 1335-1340.
43.	Takada K, Katada Y, Ito S, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford), 2020, 59(5): 1084-1093.
44.	Kurita T, Yasuda S, Oba K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford), 2015, 54(8): 1536.
45.	Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem, 2000, 7(7): 731-748.

1. Broen JCA, van Laar JM. Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology. Nat Rev Rheumatol, 2020, 16(3): 167-178.
2. Gizinski AM, Fox DA. T cell subsets and their role in the pathogenesis of rheumatic disease. Curr Opin Rheumatol, 2014, 26(2): 204-210.
3. Kapturczak MH, Meier-Kriesche HU, Kaplan B. Pharmacology of calcineurin antagonists. Transplant Proc, 2004, 36(2 Suppl): 25S-32S.
4. F?rre O. Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group. Arthritis Rheum, 1994, 37(10): 1506-1512.
5. Dougados M, Awada H, Amor B. Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients. Ann Rheum Dis, 1988, 47(2): 127-133.
6. Caccavo D, Laganà B, Mitterhofer AP, et al. Long-term treatment of systemic lupus erythematosus with cyclosporin A. Arthritis Rheum, 1997, 40(1): 27-35.
7. Filaci G, Cutolo M, Basso M, et al. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A. Rheumatology (Oxford), 2001, 40: 1431-1432.
8. Cantini F, Salvarani C, Niccoli L, et al. Treatment of thrombophlebitis of Beh?et's disease with low dose cyclosporin A. Clin Exp Rheumatol, 1999, 17(3): 391-392.
9. Watanabe N, Sakamoto K, Taniguchi H, et al. Efficacy of combined therapy with cyclosporin and low-dose prednisolone in interstitial pneumonia associated with connective tissue disease. Respiration, 2014, 87(6): 469-477.
10. Wu W, Guo L, Fu Y, et al. Interstitial lung disease in anti-MDA5 positive dermatomyositis. Clin Rev Allergy Immunol, 2021, 60(2): 293-304.
11. 馮娜, 彭守春, 李學任. 抗黑色素瘤分化相關基因5抗體陽性快速進展型間質性肺疾病的治療進展. 醫療裝備, 2021, 34: 187-189.
12. Kotani T, Makino S, Takeuchi T, et al. Early intervention with corticosteroids and cyclosporin A and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol, 2008, 35(2): 254-259.
13. Kameda H, Nagasawa H, Ogawa H, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol, 2005, 32(9): 1719-1726.
14. Fujisawa T. Management of myositis-associated interstitial lung disease. Medicina (Kaunas), 2021, 57(4): 347.
15. Romero-Bueno F, Diaz Del Campo P, Trallero-Araguás E, et al. Recommendations for the treatment of anti-melanoma differentiation-associated gene 5-positive dermatomyositis-associated rapidly progressive interstitial lung disease. Semin Arthritis Rheum, 2020, 50(4): 776-790.
16. Abe Y, Kusaoi M, Tada K, et al. Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy. Rheumatology (Oxford), 2020, 59(4): 767-771.
17. Nakazawa M, Kaneko Y, Takeuchi T. Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study. Clin Rheumatol, 2018, 37(3): 765-771.
18. Cavagna L, Caporali R, Abdì-Alì L, et al. Cyclosporine in anti-Jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol, 2013, 40(4): 484-492.
19. Go DJ, Park JK, Kang EH, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int, 2016, 36(1): 125-131.
20. Lian L, Li M, Li Y, et al. Combination therapy of tacrolimus, high doses of glucocorticosteroids, and cyclophosphamide against existing historical treatment for patients in severe conditions of interstitial lung diseases complicated with dermatomyositis: A retrospective analysis. Medicine (Baltimore), 2022, 101(24): e29108.
21. Fujisawa T, Hozumi H, Kamiya Y, et al. Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis/dermatomyositis-associated ILD: a randomized, open-label trial. Respirology, 2021, 26(4): 370-377.
22. 中國研究型醫院學會呼吸病學專業委員會. 特發性炎性肌病相關間質性肺疾病診斷和治療中國專家共識. 中華結核和呼吸雜志, 2022, 45(7): 635-650.
23. Kaneko Y, Kawahito Y, Kojima M, et al. Efficacy and safety of tacrolimus in patients with rheumatoid arthritis - a systematic review and meta-analysis. Mod Rheumatol, 2021, 31(1): 61-69.
24. Lee YH, Woo JH, Choi SJ, et al. Tacrolimus for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Scand J Rheumatol, 2010, 39(4): 271-278.
25. Matsubara S, Kondo K, Sugaya K, et al. Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Clin Rheumatol, 2012, 31(10): 1493-1498.
26. Shimojima Y, Ishii W, Matsuda M, et al. Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/ dermatomyositis: a retrospective study. BMC Musculoskelet Disord, 2012, 13: 228.
27. Yokoyama Y, Furuta S, Ikeda K, et al. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Mod Rheumatol, 2015, 25(6): 888-892.
28. Suzuki K, Kameda H, Amano K, et al. Single center prospective study of tacrolimus efficacy and safety in the treatment of various manifestations in systemic lupus erythematosus. Rheumatol Int, 2011, 31(6): 757-763.
29. Konma J, Kotani T, Shoda T, et al. Efficacy and safety of combination therapy with prednisolone and oral tacrolimus for progressive interstitial pneumonia with systemic sclerosis: A retrospective study. Mod Rheumatol, 2018, 28(6): 1009-1015.
30. Yamano Y, Taniguchi H, Kondoh Y, et al. Multidimensional improvement in connective tissue disease-associated interstitial lung disease: two courses of pulse dose methylprednisolone followed by low-dose prednisone and tacrolimus. Respirology, 2018, 23: 1041-1048.
31. Witt LJ, Demchuk C, Curran JJ, et al. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther, 2016, 36: 46-52.
32. Suzuka T, Kotani T, Takeuchi T, et al. Efficacy and safety of oral high-trough level tacrolimus in acute/subacute interstitial pneumonia with dermatomyositis. Int J Rheum Dis, 2019, 22(2): 303-313.
33. Tsuji H, Nakashima R, Hosono Y, et al. Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis. Arthritis Rheumatol, 2020, 72(3): 488-498.
34. Oddis CV, Sciurba FC, Elmagd KA, et al. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet, 1999, 353(9166): 1762-1763.
35. Wilkes MR, Sereika SM, Fertig N, et al. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum, 2005, 52(8): 2439-2446.
36. Labirua-Iturburu A, Selva-O'Callaghan A, Martínez-Gómez X, et al. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol, 2013, 31(3): 436-439.
37. Sharma N, Putman MS, Vij R, et al. Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort. J Rheumatol, 2017, 44(11): 1612-1618.
38. Hozumi H, Fujisawa T, Nakashima R, et al. Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease: a propensity score-matched analysis. J Rheumatol, 2019, 46(5): 509-517.
39. Chen Y, Bai Z, Zhang Z, et al. The efficacy and safety of tacrolimus on top of glucocorticoids in the management of IIM-ILD: a retrospective and prospective study. Front Immunol, 2022, 13: 978429.
40. Takei R, Yamano Y, Kataoka K, et al. Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease. Respir Investig, 2020, 58(2): 83-90.
41. Yoshifuji H, Fujii T, Kobayashi S, et al. Anti-aminoacyl-tRNA synthetase antibodies in clinical course prediction of interstitial lung disease complicated with idiopathic inflammatory myopathies. Autoimmunity, 2006, 39(3): 233-241.
42. Isoda K, Kotani T, Takeuchi T, et al. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. Rheumatol Int, 2017, 37(8): 1335-1340.
43. Takada K, Katada Y, Ito S, et al. Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis/dermatomyositis: a single-arm clinical trial. Rheumatology (Oxford), 2020, 59(5): 1084-1093.
44. Kurita T, Yasuda S, Oba K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford), 2015, 54(8): 1536.
45. Dumont FJ. FK506, an immunosuppressant targeting calcineurin function. Curr Med Chem, 2000, 7(7): 731-748.

Previous Article
肺部微生物組與肺癌發展及治療關系的研究進展

Chinese Journal of Respiratory and Critical Care Medicine

鈣調磷酸酶抑制劑在特發性炎性肌病相關性間質性肺病中的研究進展

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content